Issues lobbied + lobbyists
HCR — Health Issues
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Lobbyists: SWARNA VALLURUPALLI; ms HANNAH BETH CORNWELL; MATTHEW O SCHUMAKER; KYLE HILL (covered position: Leg. Director, Rep. Suzan DelBene (1/19-7/22); Sr. Leg. Asst., Rep. Suzan DelBene (10/17-1/19); Health Policy Advisor, Rep. Steve Israel (2/16-12/16); Leg. Asst., Rep. Steve Israel (5/13-12/14); Staff Asst., Rep. Steve Israel (12/12-05/13)) [new]
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
MMM — Medicare/Medicaid
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Lobbyists: MATTHEW O SCHUMAKER; SWARNA VALLURUPALLI; ms HANNAH BETH CORNWELL; KYLE HILL (covered position: Leg. Director, Rep. Suzan DelBene (1/19-7/22); Sr. Leg. Asst., Rep. Suzan DelBene (10/17-1/19); Health Policy Advisor, Rep. Steve Israel (2/16-12/16); Leg. Asst., Rep. Steve Israel (5/13-12/14); Staff Asst., Rep. Steve Israel (12/12-05/13)) [new]
Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); Congressional Budget Office (CBO); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); SENATE; Vice President of the U.S.; White House Office
TAX — Taxation/Internal Revenue Code
Corporate tax reform; H.R. 1414 - Cameron's Law, Preservation of Orphan Drug Tax Credit.
Lobbyists: SWARNA VALLURUPALLI
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
BUD — Budget/Appropriations
Education about non-opioid pain therapies and patient access to non-opioid medicines, updates on coverage progress at the VHA and CMS.
Lobbyists: SWARNA VALLURUPALLI; ms HANNAH BETH CORNWELL; MATTHEW O SCHUMAKER; KYLE HILL (covered position: Leg. Director, Rep. Suzan DelBene (1/19-7/22); Sr. Leg. Asst., Rep. Suzan DelBene (10/17-1/19); Health Policy Advisor, Rep. Steve Israel (2/16-12/16); Leg. Asst., Rep. Steve Israel (5/13-12/14); Staff Asst., Rep. Steve Israel (12/12-05/13)) [new]
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
TRD — Trade (domestic/foreign)
Intellectual property reforms to address unfair trade practices in Argentina and Russia.
Lobbyists: MATTHEW O SCHUMAKER
Government entities lobbied: U.S. Trade Representative (USTR)
VET — Veterans
Issues related to veteran's access to non-opioid alternatives and implementation of report language in the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (PL 119-37).
Lobbyists: ms HANNAH BETH CORNWELL; MATTHEW O SCHUMAKER; SWARNA VALLURUPALLI; KYLE HILL (covered position: Leg. Director, Rep. Suzan DelBene (1/19-7/22); Sr. Leg. Asst., Rep. Suzan DelBene (10/17-1/19); Health Policy Advisor, Rep. Steve Israel (2/16-12/16); Leg. Asst., Rep. Steve Israel (5/13-12/14); Staff Asst., Rep. Steve Israel (12/12-05/13)) [new]
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
DEF — Defense
Issues related to the Defense Health Agency and service member access to non-opioid alternatives, including reinstating the DHA Benefits Advisory Panel and the structured formulary management process.
Lobbyists: ms HANNAH BETH CORNWELL; SWARNA VALLURUPALLI; MATTHEW O SCHUMAKER
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE